{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:40:01Z","timestamp":1792003201761,"version":"4.4.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00259-019-04411-7","type":"journal-article","created":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T03:24:13Z","timestamp":1564025053000},"page":"2298-2310","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":132,"title":["Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics"],"prefix":"10.1007","volume":"46","author":[{"given":"Romain-David","family":"Seban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Nemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lien","family":"Marabelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Deutsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Ammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Moya-Plana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima-Zohra","family":"Mokrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn D.","family":"Gartrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace","family":"Finkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie E.","family":"Bigorgne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence H.","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Saenger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1322-0710","authenticated-orcid":false,"given":"Laurent","family":"Dercle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"key":"4411_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u201330.","journal-title":"N Engl J Med"},{"key":"4411_CR2","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med. 2015;372:2521\u201332.","journal-title":"N Engl J Med"},{"key":"4411_CR3","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1001\/jama.2016.4059","volume":"315","author":"A Ribas","year":"2016","unstructured":"Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of Pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA. 2016;315:1600\u20139.","journal-title":"JAMA."},{"key":"4411_CR4","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1093\/annonc\/mdy330","volume":"29","author":"AC Tan","year":"2018","unstructured":"Tan AC, Emmett L, Lo S, Liu V, Kapoor R, Carlino MS, et al. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Ann Oncol. 2018;29:2115\u201320.","journal-title":"Ann Oncol"},{"key":"4411_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.ejca.2016.05.031","volume":"65","author":"L Dercle","year":"2016","unstructured":"Dercle L, Ammari S, Champiat S, Massard C, Fert\u00e9 C, Taihi L, et al. Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1\/\u2212L1 therapy. Eur J Cancer. 2016;65:33\u201342.","journal-title":"Eur J Cancer"},{"key":"4411_CR6","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.mehy.2018.05.005","volume":"116","author":"B-D Qin","year":"2018","unstructured":"Qin B-D, Jiao X-D, Zang Y-S. Tumor mutation burden to tumor burden ratio and prediction of clinical benefit of anti-PD-1\/PD-L1 immunotherapy. Med Hypotheses. 2018;116:111\u20133.","journal-title":"Med Hypotheses"},{"key":"4411_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2967\/jnumed.117.193011","volume":"59","author":"L Dercle","year":"2018","unstructured":"Dercle L, Seban R-D, Lazarovici J, Schwartz LH, Houot R, Ammari S, et al. 18F-FDG PET and CT scans detect new imaging patterns of response and progression in patients with Hodgkin lymphoma treated by anti-programmed death 1 immune checkpoint inhibitor. J Nucl Med. 2018;59:15\u201324.","journal-title":"J Nucl Med"},{"key":"4411_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejca.2017.12.015","volume":"91","author":"L Dercle","year":"2018","unstructured":"Dercle L, Ammari S, Seban R-D, Schwartz LH, Houot R, Labaied N, et al. Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma. Eur J Cancer. 2018;91:136\u201344.","journal-title":"Eur J Cancer"},{"key":"4411_CR9","doi-asserted-by":"crossref","unstructured":"Joseph RW, Elassaiss-Schaap J, Kefford RF, Hwu W-J, Wolchok JD, Joshua AM, et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with Pembrolizumab. Clin Cancer Res. 2018;24(20):4960\u20137.","DOI":"10.1158\/1078-0432.CCR-17-2386"},{"key":"4411_CR10","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert C, Ribas A, Hamid O, Daud A, Wolchok JD, Joshua AM, et al. Durable complete response after discontinuation of Pembrolizumab in patients with metastatic melanoma. J Clin Oncol. 2018;36:1668\u201374.","journal-title":"J Clin Oncol"},{"key":"4411_CR11","doi-asserted-by":"publisher","first-page":"e266","DOI":"10.1097\/RLU.0000000000001205","volume":"41","author":"SH Son","year":"2016","unstructured":"Son SH, Kang SM, Jeong SY, Lee S-W, Lee S-J, Lee J, et al. Prognostic value of volumetric parameters measured by pretreatment 18F FDG PET\/CT in patients with cutaneous malignant melanoma. Clin Nucl Med. 2016;41:e266\u201373.","journal-title":"Clin Nucl Med"},{"key":"4411_CR12","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13550-018-0433-1","volume":"8","author":"M Tomita","year":"2018","unstructured":"Tomita M, Yasui H, Higashikawa K, Nakajima K, Takakura H, Shiga T, et al. Anti PD-1 treatment increases [18F]FDG uptake by cancer cells in a mouse B16F10 melanoma model. EJNMMI Res. 2018;8:82.","journal-title":"EJNMMI Res"},{"key":"4411_CR13","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"4411_CR14","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1016\/j.cell.2018.09.018","volume":"175","author":"M Angelova","year":"2018","unstructured":"Angelova M, Mlecnik B, Vasaturo A, Bindea G, Fredriksen T, Lafontaine L, et al. Evolution of metastases in space and time under immune selection. Cell. 2018;175:751\u2013765.e16.","journal-title":"Cell"},{"key":"4411_CR15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger M, Rowan AJ, Horswell S, Math M, Larkin J, Endesfelder D, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366:883\u201392.","journal-title":"N Engl J Med"},{"key":"4411_CR16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00259-012-2314-6","volume":"40","author":"J Salamon","year":"2013","unstructured":"Salamon J, Derlin T, Bannas P, Busch JD, Herrmann J, Bockhorn M, et al. Evaluation of intratumoural heterogeneity on 18F-FDG PET\/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging. 2013;40:685\u201392.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4411_CR17","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1007\/s00330-017-5063-x","volume":"28","author":"L Dercle","year":"2018","unstructured":"Dercle L, Hartl D, Rozenblum-Beddok L, Mokrane F-Z, Seban R-D, Yeh R, et al. Diagnostic and prognostic value of 18F-FDG PET, CT, and MRI in perineural spread of head and neck malignancies. Eur Radiol. 2018;28:1761\u201370.","journal-title":"Eur Radiol"},{"key":"4411_CR18","doi-asserted-by":"crossref","unstructured":"Sachpekidis C, Larrib\u00e8re L, Kopp-Schneider A, Hassel JC, Dimitrakopoulou-Strauss A. Can benign lymphoid tissue changes in 18F-FDG PET\/CT predict response to immunotherapy in metastatic melanoma? Cancer Immunol Immunother. 2019;68(2):297\u2013303.","DOI":"10.1007\/s00262-018-2279-9"},{"key":"4411_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/cmi.2011.47","volume":"9","author":"E Zhao","year":"2012","unstructured":"Zhao E, Xu H, Wang L, Kryczek I, Wu K, Hu Y, et al. Bone marrow and the control of immunity. Cell Mol Immunol. 2012;9:11\u20139.","journal-title":"Cell Mol Immunol"},{"key":"4411_CR20","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s00262-016-1953-z","volume":"66","author":"KR Jordan","year":"2017","unstructured":"Jordan KR, Kapoor P, Spongberg E, Tobin RP, Gao D, Borges VF, et al. Immunosuppressive myeloid-derived suppressor cells are increased in splenocytes from cancer patients. Cancer Immunol Immunother. 2017;66:503\u201313.","journal-title":"Cancer Immunol Immunother"},{"key":"4411_CR21","doi-asserted-by":"publisher","unstructured":"Zilio S, Serafini P. Neutrophils and granulocytic MDSC: the Janus god of cancer immunotherapy. Vaccines (Basel). 2016. https:\/\/doi.org\/10.3390\/vaccines4030031 .","DOI":"10.3390\/vaccines4030031"},{"key":"4411_CR22","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1073\/pnas.1113744109","volume":"109","author":"V Cortez-Retamozo","year":"2012","unstructured":"Cortez-Retamozo V, Etzrodt M, Newton A, Rauch PJ, Chudnovskiy A, Berger C, et al. Origins of tumor-associated macrophages and neutrophils. Proc Natl Acad Sci USA. 2012;109:2491\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"4411_CR23","doi-asserted-by":"publisher","first-page":"e1574197","DOI":"10.1080\/2162402X.2019.1574197","volume":"8","author":"R-D Seban","year":"2019","unstructured":"Seban R-D, Robert C, Dercle L, Yeh R, Dunant A, Reuze S, et al. Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy. Oncoimmunology. 2019;8:e1574197.","journal-title":"Oncoimmunology"},{"key":"4411_CR24","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1097\/RLU.0b013e3181ef0905","volume":"35","author":"H-Y Nam","year":"2010","unstructured":"Nam H-Y, Kim S-J, Kim I-J, Kim B-S, Pak K, Kim K. The clinical implication and prediction of diffuse splenic FDG uptake during cancer surveillance. Clin Nucl Med. 2010;35:759\u201363.","journal-title":"Clin Nucl Med"},{"key":"4411_CR25","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/j.cell.2018.10.038","volume":"175","author":"M Sade-Feldman","year":"2018","unstructured":"Sade-Feldman M, Yizhak K, Bjorgaard SL, Ray JP, de Boer CG, Jenkins RW, et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell. 2018;175:998\u20131013.e20.","journal-title":"Cell."},{"key":"4411_CR26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00432-013-1545-7","volume":"140","author":"HW Chung","year":"2014","unstructured":"Chung HW, Lee KY, Kim HJ, Kim WS, So Y. FDG PET\/CT metabolic tumor volume and total lesion glycolysis predict prognosis in patients with advanced lung adenocarcinoma. J Cancer Res Clin Oncol. 2014;140:89\u201398.","journal-title":"J Cancer Res Clin Oncol"},{"key":"4411_CR27","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2967\/jnumed.113.131847","volume":"55","author":"JW Lee","year":"2014","unstructured":"Lee JW, Kang CM, Choi HJ, Lee WJ, Song SY, Lee J-H, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis on preoperative 18F-FDG PET\/CT in patients with pancreatic cancer. J Nucl Med. 2014;55:898\u2013904.","journal-title":"J Nucl Med"},{"key":"4411_CR28","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3413\/Nukmed-0356-10-09","volume":"50","author":"S Kang","year":"2011","unstructured":"Kang S, Ahn B-C, Hong CM, Song B-I, Lee HJ, Jeong SY, et al. Can (18)F-FDG PET\/CT predict recurrence in patients with cutaneous malignant melanoma? Nuklearmedizin. 2011;50:116\u201321.","journal-title":"Nuklearmedizin"},{"key":"4411_CR29","doi-asserted-by":"publisher","first-page":"9523","DOI":"10.1200\/JCO.2016.34.15_suppl.9523","volume":"34","author":"ANM Wong","year":"2016","unstructured":"Wong ANM, Callahan J, Beresford J, Herschtal A, Fullerton S, Milne D, et al. Spleen to liver ratio (SLR): novel PET imaging biomarker for prediction of overall survival after ipilimumab and anti-PD1 in patients with metastatic melanoma. JCO. 2016;34:9523.","journal-title":"JCO"},{"key":"4411_CR30","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","volume":"19","author":"R Sun","year":"2018","unstructured":"Sun R, Limkin EJ, Vakalopoulou M, Dercle L, Champiat S, Han SR, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19:1180\u201391.","journal-title":"Lancet Oncol"},{"key":"4411_CR31","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/nature04186","volume":"438","author":"RN Kaplan","year":"2005","unstructured":"Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820\u20137.","journal-title":"Nature"},{"key":"4411_CR32","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/S1535-6108(02)00153-8","volume":"2","author":"S Hiratsuka","year":"2002","unstructured":"Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2002;2:289\u2013300.","journal-title":"Cancer Cell"},{"key":"4411_CR33","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature12984","volume":"505","author":"SJ Morrison","year":"2014","unstructured":"Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature. 2014;505:327\u201334.","journal-title":"Nature"},{"key":"4411_CR34","doi-asserted-by":"publisher","first-page":"e1408750","DOI":"10.1080\/2162402X.2017.1408750","volume":"7","author":"N Kamran","year":"2018","unstructured":"Kamran N, Li Y, Sierra M, Alghamri MS, Kadiyala P, Appelman HD, et al. Melanoma induced immunosuppression is mediated by hematopoietic dysregulation. Oncoimmunology. 2018;7:e1408750.","journal-title":"Oncoimmunology"},{"key":"4411_CR35","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9:162\u201374.","journal-title":"Nat Rev Immunol"},{"key":"4411_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4329\/wjr.v9.i2.27","volume":"9","author":"M Bauckneht","year":"2017","unstructured":"Bauckneht M, Piva R, Sambuceti G, Grossi F, Morbelli S. Evaluation of response to immune checkpoint inhibitors: is there a role for positron emission tomography? World J Radiol. 2017;9:27\u201333.","journal-title":"World J Radiol"},{"key":"4411_CR37","doi-asserted-by":"crossref","unstructured":"Munn LL. Cancer and inflammation. Wiley Interdiscip Rev Syst Biol Med. 2017;9(2):e1370.","DOI":"10.1002\/wsbm.1370"},{"key":"4411_CR38","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.hoc.2014.02.005","volume":"28","author":"K Margolin","year":"2014","unstructured":"Margolin K. Introduction to the role of the immune system in melanoma. Hematol Oncol Clin North Am. 2014;28:537\u201358.","journal-title":"Hematol Oncol Clin North Am"},{"key":"4411_CR39","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/978-3-0348-0837-8_17","volume":"816","author":"GB Maru","year":"2014","unstructured":"Maru GB, Gandhi K, Ramchandani A, Kumar G. The role of inflammation in skin cancer. Adv Exp Med Biol. 2014;816:437\u201369.","journal-title":"Adv Exp Med Biol"},{"key":"4411_CR40","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1002\/ijc.29297","volume":"136","author":"H Jiang","year":"2015","unstructured":"Jiang H, Gebhardt C, Umansky L, Beckhove P, Schulze TJ, Utikal J, et al. Elevated chronic inflammatory factors and myeloid-derived suppressor cells indicate poor prognosis in advanced melanoma patients. Int J Cancer. 2015;136:2352\u201360.","journal-title":"Int J Cancer"},{"key":"4411_CR41","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1158\/1078-0432.CCR-15-0676","volume":"21","author":"C Gebhardt","year":"2015","unstructured":"Gebhardt C, Sevko A, Jiang H, Lichtenberger R, Reith M, Tarnanidis K, et al. Myeloid cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with Ipilimumab. Clin Cancer Res. 2015;21:5453\u20139.","journal-title":"Clin Cancer Res"},{"key":"4411_CR42","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1007\/s00259-012-2182-0","volume":"39","author":"E Bastiaannet","year":"2012","unstructured":"Bastiaannet E, Hoekstra OS, de Jong JR, Brouwers AH, Suurmeijer AJH, Hoekstra HJ. Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma. Eur J Nucl Med Mol Imaging. 2012;39:1592\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4411_CR43","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1007\/s00259-016-3425-2","volume":"43","author":"E Lopci","year":"2016","unstructured":"Lopci E, Toschi L, Grizzi F, Rahal D, Olivari L, Castino GF, et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. Eur J Nucl Med Mol Imaging. 2016;43:1954\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"4411_CR44","doi-asserted-by":"crossref","unstructured":"Boursi B, Werner TJ, Gholami S, Margalit O, Baruch E, Markel G, et al. Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma. Melanoma Res. 2018.","DOI":"10.1097\/CMR.0000000000000566"},{"key":"4411_CR45","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143\u201352.","journal-title":"Lancet Oncol"},{"key":"4411_CR46","doi-asserted-by":"publisher","first-page":"32","DOI":"10.14735\/amko20173S32","volume":"30","author":"\u0160 Houdek","year":"2017","unstructured":"Houdek \u0160, B\u00fcchler T, Kindlov\u00e1 E. Comparison of RECIST 1.1 and iRECIST for response evaluation in solid Tumours. Klin Onkol. 2017;30:32\u20139.","journal-title":"Klin Onkol"},{"key":"4411_CR47","doi-asserted-by":"publisher","first-page":"e1413520","DOI":"10.1080\/2162402X.2017.1413520","volume":"7","author":"M Shen","year":"2018","unstructured":"Shen M, Wang J, Yu W, Zhang C, Liu M, Wang K, et al. A novel MDSC-induced PD-1-PD-L1+ B-cell subset in breast tumor microenvironment possesses immuno-suppressive properties. Oncoimmunology. 2018;7:e1413520.","journal-title":"Oncoimmunology."},{"key":"4411_CR48","doi-asserted-by":"crossref","unstructured":"Liu Y, Wei G, Cheng WA, Dong Z, Sun H, Lee VY, et al. Targeting myeloid-derived suppressor cells for cancer immunotherapy. Cancer Immunol Immunother. 2018;67(8):1181\u201395.","DOI":"10.1007\/s00262-018-2175-3"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04411-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00259-019-04411-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-019-04411-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T02:52:10Z","timestamp":1610592730000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00259-019-04411-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4411"],"URL":"https:\/\/doi.org\/10.1007\/s00259-019-04411-7","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,25]]},"assertion":[{"value":"28 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have declared no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}